<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39359433</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2008-6164</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Season>Fall</Season></PubDate></JournalIssue><Title>Caspian journal of internal medicine</Title><ISOAbbreviation>Caspian J Intern Med</ISOAbbreviation></Journal><ArticleTitle>COVID-19 infection after vaccination.</ArticleTitle><Pagination><StartPage>644</StartPage><EndPage>650</EndPage><MedlinePgn>644-650</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22088/cjim.15.4.644</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Although vaccination is the most effective and specific approach for prevention of infectious diseases, but in a small percentage of vaccinated person's breakthrough infections can occur. This study aimed to determine the effectiveness of different common <i>coronavirus</i> vaccines in this area.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">109 COVID-19 vaccinated patients were enrolled, with different types of vaccines (Sinopharm, AstraZeneca, Sputnic, Bharath, CovIran Barkat and Pasto-CoV) and time of administration in 2021 in Babol, Iran. Patients after 14 days of administration of the final dose of corona vaccines with positive COVID-19 RT-PCR test entered to study. Patients' data such as RT-PCR, type of vaccine, age, sex and outcome were collected using electronic medical records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">47 patients were not fully vaccinated, 62 had two vaccine doses and 51 were fully vaccinated and considered to a breakthrough infection. Although, most of the patients with <i>SARS-CoV-2</i> infection were either mild (n=18 [16.56%]), or moderate (n=86 [78.9%]), 5 (4.6%) patients had severe or critical illness, of whom 3 admitted in intensive care unit, 3 intubated, and 4 died. The average age of the participants with COVID-19 infections was 61.23 ± 19.91 years.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Based on our results, the <i>COVID-19</i> breakthrough occurring with two doses of current vaccines were mild and moderate.</AbstractText><CopyrightInformation>© The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baziboroun</LastName><ForeName>Mana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseinzadeh</LastName><ForeName>Sayareh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Part of Infectious Control, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gholinia</LastName><ForeName>Hemmat</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Farzin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yahyapour</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Caspian J Intern Med</MedlineTA><NlmUniqueID>101523876</NlmUniqueID><ISSNLinking>2008-6164</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breakthrough</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359433</ArticleId><ArticleId IdType="pmc">PMC11444105</ArticleId><ArticleId IdType="doi">10.22088/cjim.15.4.644</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580:576–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32346146</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado BAS, Hodel KVS, Fonseca LMDS, et al. The importance of vaccination in the context of the COVID-19 pandemic: A brief update regarding the use of vaccines. Vaccines (Basel) 2022;10:591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9027942</ArticleId><ArticleId IdType="pubmed">35455340</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg Health Eur. 2021:100150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261633</ArticleId><ArticleId IdType="pubmed">34250518</ArticleId></ArticleIdList></Reference><Reference><Citation>Petter E, Mor O, Zuckerman N, et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. MedRxiv. 2021:2021–02.</Citation></Reference><Reference><Citation>Stephenson J. COVID-19 vaccinations in nursing home residents and staff give robust protection, though breakthrough infections still possible. JAMA Health Forum. 2021;2:e211195.</Citation><ArticleIdList><ArticleId IdType="pubmed">36218817</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021;15:1007–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091733</ArticleId><ArticleId IdType="pubmed">33991805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384:2212–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117968</ArticleId><ArticleId IdType="pubmed">33882219</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26:1770–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35302230</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BD, Storlie CB, Tande AJ, Sampathkumar P. Real-World Incidence of Breakthrough Coronavirus Disease 2019 Hospitalization After Vaccination vs Natural Infection in a Large, Local, Empaneled Primary Care Population Using Time-to-Event Analysis. Clin Infect Dis. 2022;75:1239–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903437</ArticleId><ArticleId IdType="pubmed">35247261</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O, Ribes I, Boix V, et al. Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors. Int J Infect Dis. 2022;118:89–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841006</ArticleId><ArticleId IdType="pubmed">35172182</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008750</ArticleId><ArticleId IdType="pubmed">33755376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Six months of COVID vaccines: what 1 7 billion doses have taught scientists. Nature. 2021;594:164–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34089016</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382:1199–1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27:1652–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261136</ArticleId><ArticleId IdType="pubmed">34245907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein NR, Rasheed BN, Naqid IA, et al. A study of SARS-CoV-2 delta variant breakthrough infections and side effects of the Oxford-AstraZeneca vaccine. Public Health Pract (Oxf) 2022;4:100303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339090</ArticleId><ArticleId IdType="pubmed">35936975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 Vaccine Effectiveness with Patient Age and Comorbidities. Available from: https://doi.org/10.1101/2021.03.16.21253686. [Preprint]</Citation></Reference><Reference><Citation>Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health. 2020;8:e488–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097845</ArticleId><ArticleId IdType="pubmed">32119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Uschner D, Bott M, Lagarde WH, et al. Breakthrough SARS-CoV-2 infections after vaccination in North Carolina. Vaccines (Basel) 2022;10:1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9695352</ArticleId><ArticleId IdType="pubmed">36423018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>